Putting cardiovascular risk into perspective

Abstract

Get full access to this article

View all access options for this article.

References

Genest

McPherson

Frohlich

. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations. Can J Cardiol 2009;25:567-79.

Tsuyuki

Johnson

Teo

. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 2002;162:1149-55.

Tsuyuki

Olson

Dubyk

. Effect of community pharmacist intervention on cholesterol levels in patients at high risk of cardiovascular events: the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus). Am J Med 2004;116:130-3.

Khot

Bajzer

. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290:898-904.

Castelli

. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996;124(Suppl):S1-S9.

Ridker

Danielson

Fonseca

. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.

Bisoendial

Kastelein

Stroes

. C-reactive protein and atherogenesis: from fatty streak to clinical event. Atherosclerosis 2007;195:e10-e18.

Heart & Stroke Foundation. Angina. Available: www.heartandstroke.com/site/c.ikIQLcMWJtE/b.3484055/k.52CA/Heart_disease__Angina.htm (accessed Oct. 23, 2012).